Filing Details
- Accession Number:
- 0001209191-16-134106
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-07-27 16:48:34
- Reporting Period:
- 2016-07-25
- Filing Date:
- 2016-07-27
- Accepted Time:
- 2016-07-27 16:48:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1274792 | Merrimack Pharmaceuticals Inc | MACK | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1632653 | M. Birgit Schoeberl | C/O Merrimack Pharmaceuticals, Inc. One Kendall Square, Suite B7201 Cambridge MA 02139 | Head Of Discovery | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-07-25 | 50,000 | $2.12 | 115,657 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-07-25 | 50,000 | $5.50 | 65,657 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2016-07-25 | 50,000 | $0.00 | 50,000 | $2.12 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2016-08-01 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.39 to $5.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- This option is fully vested.
Billionaire Hedge Funds
